Episode 895
TWiV 895: COVID-19 clinical update #112 with Dr. Daniel Griffin
April 30, 202235m 37s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Seroprevalence of Infection-Induced Antibodies (CDC)
- Authorization for Vaccine in Young Children Filed (Moderna)
- Public Health Impact of Vaccines in US (BMJ)
- FDA authorizes first approved treatment for children (FDA)
- Phase 2 Data for Sabizabulin (Veru Pharma)
- Clinical Characteristics of Post Infection Inflammation (The Lancet)
- Fact Sheet for Providers on Evusheld (FDA)
- Fact Sheet for Providers on Paxlovid (FDA)
- Provider Referral for EvuSheld (Northwell Health)
- Contribute to ASTMH fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 895
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]